Public company, workplace, funding, and market signals
Updated Aug 16, 2026
ArsenalBio is a clinical-stage biotechnology company developing programmable autologous T-cell therapies for solid tumors. Its platform combines CRISPR-enabled genome engineering, synthetic biology, computational biology and machine learning to create multifunctional CAR-T medicines with logic-gated tumor targeting and resistance to the tumor microenvironment.
Primary product
AB-2100, an autologous integrated-circuit T-cell therapy in Phase 1/2 development for relapsed or refractory clear-cell renal cell carcinoma. ArsenalBio also has preclinical programs and partnered AB-4000-series programs.
Founded
2019
Headquarters
South San Francisco, California, United States
Team size
Approximately 127 employees after the September-November 2025 restructuring; historical headcount was approximately 265 in September 2024.
Industry
Biotechnology
Sub-industry
Cell and gene therapy; cancer immunotherapy; synthetic biology
Offices
Business model
Stage
Series C; privately held clinical-stage biotech
Total raised
$630M
Latest round
Series C · Sep 2024
Latest amount
$325M
Sep 2024 · ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures and other participating investors
Sep 2022
Oct 2019 · Westlake Village BioPartners
Jan 2018 · Sean Parker and Westlake Village BioPartners
Leadership
Chairman, Chief Executive Officer and Co-Founder
Chief Scientific Officer and Co-Founder
Chief Technical Operations Officer
Bee Nguyen
Chief People Officer
Chief Medical Officer
Chief Technology Officer
Vice President, Intellectual Property
Founders
Jane Grogan, PhD
Founding management team member
Co-Founder
Michael Kalos, PhD
Founding management team member
Co-Founder and Board Observer
Investors
The company describes a people-first, diverse and inclusive culture centered on a shared mission to help patients with incurable disease. Its stated operating principles emphasize collaboration, unity, inclusivity, scientific rigor and prioritizing team outcomes over individual goals.
Compensation
ArsenalBio advertises generous compensation packages and benefits, but publicly available company materials reviewed did not provide salary bands, equity details or a definitive visa-sponsorship policy.
Benefits
Differentiators
Technology
Customers
Estimated revenue
$1 million-$10 million annually; third-party estimate approximately $8 million
Estimated monthly visits
4.3K
Traffic estimate as of Jun 2026
ArsenalBio confirmed a restructuring and approximately 50% workforce reduction as it shifted resources from early-stage research toward clinical development. A California WARN filing reportedly covered at least 100 South San Francisco employees effective November 14, 2025; approximately 127 employees remained.
SourceFollowing its $325 million Series C, ArsenalBio prioritized AB-2100 and prostate-cancer development and indicated that former lead asset AB-1015 was not expected to advance beyond Phase 1 at that time.
SourceManagement cited the need to extend cash runway, reflecting financing and operating-risk pressure despite the large 2024 financing.
SourceFierce Biotech · Sep 2025
ArsenalBio confirmed a roughly 50% workforce reduction and a strategic shift toward clinical-stage programs, with approximately 127 employees remaining.
ArsenalBio · Jan 2025
Bristol Myers Squibb exercised an exclusive license option for the AB-4000 series. ArsenalBio remains eligible for additional milestones and royalties.
ArsenalBio · Sep 2024
The company closed an oversubscribed Series C to advance its solid-tumor cell-therapy pipeline and platform, with participation from ARCH, Regeneron Ventures, NVentures, T. Rowe Price and returning investors.
ArsenalBio · May 2024
The company presented data on logic-gated CAR-T cells, mechanisms for overcoming tumor immunosuppression and CRISPR-based approaches to reduce T-cell exhaustion.
ArsenalBio · Apr 2024
AB-2100 entered a multicenter Phase 1/2 trial for clear-cell renal cell carcinoma, becoming ArsenalBio’s second internally discovered T-cell candidate to enter clinical development.
1 job at ArsenalBio